{'fraction_non_alphanumeric': 0.03807615230460922, 'fraction_numerical': 0.0, 'mean_word_length': 5.756756756756757, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Tenecteplase: single-bolus thrombolytic therapy for acute myocardial infarction.

Tenecteplase is a new, fibrin-specific, third generation thrombolytic agent produced by recombinant DNA technology. It was developed by Genentech, Incorporated (South San Francisco, California) and marketed under the trade-name TNKase. Tenecteplase is the first "clot-busting" drug to be formulated for administration as a single, rapid, injectable dose and offers prompt administration for the treatment of acute MI.